Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding AG    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
04/01/2021 04/06/2021 04/07/2021 04/08/2021 04/09/2021 Date
305.4(c) 305.3(c) 302.2(c) 307.15(c) 309.65(c) Last
961 132 1 003 282 1 326 517 1 164 061 1 021 222 Volume
-0.02% -0.03% -1.02% +1.64% +0.81% Change
More quotes
Financials
Sales 2021 60 335 M 65 234 M 65 234 M
Net income 2021 14 738 M 15 935 M 15 935 M
Net cash position 2021 4 797 M 5 187 M 5 187 M
P/E ratio 2021 17,8x
Yield 2021 3,05%
Sales 2022 62 347 M 67 410 M 67 410 M
Net income 2022 15 890 M 17 180 M 17 180 M
Net cash position 2022 12 336 M 13 338 M 13 338 M
P/E ratio 2022 16,7x
Yield 2022 3,16%
Capitalization 267 B 288 B 288 B
EV / Sales 2021 4,34x
EV / Sales 2022 4,08x
Nbr of Employees 101 465
Free-Float 82,6%
More Financials
Company
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The... 
Sector
Pharmaceuticals
Calendar
04/21 | 08:00amSales and Revenue Call
More about the company
Notations Surperformance© of Roche Holding AG
Trading Rating : Investor Rating :
More Ratings
All news about ROCHE HOLDING AG
04/09CHUGAI PHARMACEUTICAL  : Conducts Disease Awareness Activities Internally and Ex..
AQ
04/09Regeneron Pharma Covid-19 Treatment Recommended by National Institutes of Hea..
DJ
04/08Biogen Licenses Actemra Biosimilar Candidate From Bio-Thera Solutions
DJ
04/08ROCHE  : to Present New Data on New, Potential Treatments for Neurological Disor..
MT
04/08ROCHE  : New Genentech Data at 2021 AAN Highlight Impact and Breadth of Expandin..
BU
04/08PRESS RELEASE  : New Roche data at 2021 AAN -3-
DJ
04/08ROCHE  : New Roche data at 2021 AAN highlight impact and breadth of expanding ne..
AQ
04/08PRESS RELEASE  : New Roche data at 2021 AAN -2-
DJ
04/08PRESS RELEASE  : New Roche data at 2021 AAN highlight impact and breadth of expa..
DJ
04/07ROCHE  : MHRA - Early Access continues during the coronavirus (COVID-19) pandemi..
AQ
04/07Global markets live: Morgan Stanley, Toshiba, Roche…
04/07ROCHE  : Launches Elecsys Anti-p53 Test to Help in Diagnosing Cancer Types
MT
04/07ROCHE  : launches Elecsys Anti-p53 immunoassay to aid diagnosis of various cance..
AQ
04/07PRESS RELEASE  : Roche launches Elecsys Anti-p53 immunoassay to aid diagnosis of..
DJ
04/07ROCHE HOLDINGS AG  : JP Morgan reiterates its Neutral rating
MD
More news
News in other languages on ROCHE HOLDING AG
04/09ROCHE : le NIH recommande un cocktail corona de Regeneron
04/09ROCHE-PARTNER REGENERON : Corona-Cocktail von NIH nachdrücklich empfohlen
04/09Aktien Schweiz etwas fester - US-Vorgaben stützen
04/08Aktien Schweiz freundlich - US-Notenbank beruhigt Anleger
04/08Roche présente des données de son portefeuille de neurosciences aux Etats-Uni..
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Stock Trading Strategies
ROCHE HOLDING AG - 2020
Close to an important medium term support level
BUY
More Stock Trading Analysis
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 353,44 CHF
Last Close Price 309,65 CHF
Spread / Highest target 42,4%
Spread / Average Target 14,1%
Spread / Lowest Target -6,35%
EPS Revisions
Managers and Directors
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Technology Officer
Christoph Franz Chairman
Urs Jaisli Chief Compliance Officer
André S. Hoffmann Vice Chairman
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING AG0.21%288 043
JOHNSON & JOHNSON2.46%424 524
PFIZER, INC.-2.31%204 161
NOVARTIS AG-3.29%197 172
MERCK & CO., INC.-6.71%193 164
ABBVIE INC.0.36%189 789